Press Release

Canine Atopic Dermatitis Market to Grow with a CAGR of 9.90% through 2028

Increase in the number of pet owners and advancements in veterinary medicine is expected to drive the Global Canine Atopic Dermatitis Market growth in the forecast period, 2024-2028

 

According to TechSci Research report, “Canine Atopic Dermatitis Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Canine Atopic Dermatitis Market stood at USD 995.60 million in 2022 and is anticipated to grow with a CAGR of 9.90% in the forecast period, 2024-2028. This can be attributed to growing veterinary care awareness. Pet owners are increasingly recognizing the importance of regular veterinary care and seeking professional advice on their pets' health. This increased awareness has led to earlier diagnosis and better management of conditions like atopic dermatitis, further driving the demand for associated treatments and solutions. Furthermore, the global nature of the canine atopic dermatitis market encourages cross-border collaboration and research. Awareness and collaboration between veterinarians, pharmaceutical companies, and pet healthcare providers are expected to grow, furthering the development of innovative treatments and diagnostic tools.

                                                                                             

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Canine Atopic Dermatitis Market

 

The primary driving force behind this market is the escalating instances of atopic dermatitis in dogs, which are exacerbated by factors such as air pollution and allergens. The most frequently observed symptoms linked to atopic dermatitis include itching, scratching, hair loss, scaly skin, and unpleasant odors. Breeds particularly prone to this canine skin condition encompass Golden Retrievers, German Shepherds, Labradors, and Pugs. The swift industrialization seen in both developed and developing nations is expected to further stimulate market expansion.

According to a report from the American College of Veterinary Dermatology (ACVD), approximately 10% to 15% of dogs were afflicted by canine atopic dermatitis in 2017. Although the exact cause of this ailment remains not entirely understood, genetic abnormalities have been identified as one of the principal contributing factors. According to a study published in the American Journal Of Veterinary Research, in the UK, Golden Retrievers exhibited a nearly 50% risk of developing canine atopic dermatitis due to geographic variations, a factor likely to enhance revenue in the years to come.

The growing number of veterinary professionals stands out as a significant factor spurring demand in this market. According to data from the American Veterinary Medical Association, there were a total of 113,394 veterinary practitioners in the United States in 2018, compared to 110,531 in 2017. Moreover, the proliferation of veterinary hospitals and clinics is further propelling market growth. Furthermore, the industry's key players are making substantial investments in research and development, launching new products, and maintaining a robust drug pipeline, all of which are expected to make substantial contributions to market expansion. For example, Kindred Biosciences, Inc. reportedly has four monoclonal antibodies for canine atopic dermatitis in their pipeline, set to debut in the next five years. In 2016, Zoetis introduced Cytopoint, a monoclonal antibody that achieved blockbuster status in 2018. The increasing demand for pet insurance and the growing concern among pet owners are expected to have a favorable impact on the market in the years to come. Moreover, stringent regulations enforced by the Food and Drug Administration (FDA) and other regulatory bodies to curtail the off-label use of human drugs in animals are bolstering market growth.

The Global Canine Atopic Dermatitis Market is segmented into product, mode of administration, distribution channel, regional distribution, and company

Based on its product, Glucocorticoids emerged as the dominant revenue generator in 2022 due to increased usage and lower costs. Topical and oral forms of glucocorticoids were identified as the primary treatment option for managing canine atopic dermatitis, with oral medications like prednisone, prednisolone, and methylprednisolone being the preferred choices for treating acute flares. These oral forms also boast minimal side effects compared to other dosage methods.

Looking ahead, the Monoclonal Antibodies (MAbs) segment is poised for significant growth during the forecast period. This treatment approach is relatively new and has demonstrated high effectiveness. Zoetis introduced its first MAb in 2016, administered every four to eight weeks to provide immediate relief from itching. Furthermore, several MAbs are currently undergoing clinical trials, with positive results expected in the coming years.

Based on distribution channel, the retail sector established its dominance in the market during 2022, primarily due to an expanded availability of products. The emergence of retail pharmacy chains plays a significant role in the distribution channel segment's market share. The implementation of digitalized systems in retail pharmacies, aimed at reducing prescription errors, is expected to drive revenue growth in the coming years. Additionally, veterinarians have increasingly turned to general pharmacies to fulfill prescriptions for medications not readily available in veterinary pharmacies, further boosting market expansion.

The rising popularity of e-commerce channels stands as a pivotal factor contributing to the attractiveness of the e-commerce segment throughout the forecast period. The convenience of selecting from websites offering a broad array of products along with comprehensive product descriptions is fueling this growth. Furthermore, discounts available on various e-commerce platforms and the growing consumer inclination towards online purchasing are anticipated to propel revenue growth in this segment.

 

Major companies operating in Global Canine Atopic Dermatitis Market are:

  • Zoetis Inc
  • Elanco Animal Health Inc
  • Virbac SA
  • Toray Industries Inc
  • AB Science SA
  • Boehringer Ingelheim GmbH
  • Kindred Biosciences Inc

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The future of the global canine atopic dermatitis market promises to be characterized by innovation and a focus on improving the lives of dogs affected by this condition. Personalized medicine, immunotherapy advancements, targeted therapies, and holistic approaches are just a few of the trends set to shape the market's growth. As the bond between humans and their canine companions deepens, so does the dedication to enhancing the well-being of dogs suffering from atopic dermatitis. The ongoing evolution of the market will bring us closer to that goal,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Canine Atopic Dermatitis Market By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others), By Mode of Administration (Topical, Oral, Injectable), By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Canine Atopic Dermatitis Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Canine Atopic Dermatitis Market.


Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com

Relevant News